Pathways changed in cluster 1 in patient PMNs . AHR, aryl hydrocarbon receptor (AHR); AMPK, AMP-activated protein kinase; EGF, epidermal growth factor; eNOS, endothelial NOS; FGF, fibrobalst growth factor; HGF, hepatocyte growth factor; mTOR, mechanistic target of rapamcyin; NGF, nerve growth factor; PDGF, platelet derived growth factor; PPAR, peroxisome proliferator-activated receptors; VEGF, vascular endothelial growth factor.